De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis

Leukemia

Volumn 14, Issue 1, 2000, Pages 183-187

  Gonzalez M ^a   Mateos, M V ^a   Garcia Sanz R ^a   Balanzategui, A ^a   Lopez Perez R ^a   Chillon M C ^a   Gonzalez D ^a   Alaejos, I ^a   San Miguel, J F ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Cell cycle; Methylation; Multiple myeloma; p16 gene

Indexed keywords

DNA; PROTEIN P16; RESTRICTION ENDONUCLEASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA METHYLATION; EXON; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE;

EID: 0343048351     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401617     Document Type: Article

References (45)

1. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3-21.
2. Greipp PR, Lust JA, O'Fallon M, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382-3387.
3. San Miguel JF, García Sanz R, González M, Moro MJ, Hernández JM, Ortega F, Borrego D, Carnero M, Casanova F, Jiménez R. Portera JA, Orfao A. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85: 448-453.
4. Sherr CJ. Mammalian G1 cyclins. Cell 1993; 73: 1059-1065.
5. Hunter T, Pines J. Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573-582.
6. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86: 841-854.
7. Weinberg RA. Tbe retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-327.
8. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9: 1149-1156.
9. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-706.
10. Hall M, Bates S, Peters G. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 1995; 11: 1581-1588.
11. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-757.
12. Stone S, Jiang P, Dayannanth P, Tavligian S, Katcher H, Pary D, Peters G, Kamb A. Complex structure and regulation of the p16 (MST1) locus. Cancer Res 1995; 55: 2988-2994.
13. Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, Ewen ME, Rollins BJ. Multiple mechanisms of p16/INK4a inactivation in non-small cell lung cancer cell lines. Cincer Res 1995; 55: 6200-6209.
14. Kamb A, Gruis NE, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440.
15. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH, Harris CC. Mutations and altered expression of p16/INK4a in human cancers. Proc Natl Sci 1994; 91: 11045-11049.
16. Drexler HG. Review of Alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 1998; 12: 845-849.
17. Delmer A, Tang K, Senamaud-Beaufort C, Paterlini P, Brechot C, Zittoun R. Alterations of cyclin dependent kinase 4 inhibitor (p16/INK4a/MTS1 ) gene structure and expression in acute lymphoblastic leukemia. Leukemia 1995; 9: 1240-1245.
18. Takeuchi M, Bartram CR, Seriu T, Miller CW, Tobler A, Janssen JW, Reiter A, Ludwig WD, Zimmermann M, Schwaller J, Lee E, Miyoshi I, Koeffler HP. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4b, p16/MTS1/INK4a, and p18 genes in acute lymphoblastic leukemia. Blood 1995; 86: 755-760.
19. Hatta Y, Hirama T, Miller CW, Yamada Y, Tomonaga M, Koeffler HP. Homozygous deletions of the p15 (MTS2) and p16 (MTS1) genes in adult T-cell leukemia. Blood 1995; 85: 2699-2704.
20. Gombart AF, Morosetti R, Miller CW, Said JW, Koeffler HP. Deletions of the cyclin dependent kinase inhibitor gnes p16/INK4a and p15/INK4b in non-Hodgkin's lymphonia. Blood 1995; 86: 1534-1539.
21. wall are associated with aggressive variants of mantle cell lymphoma. Blood 1997; 89: 272-280.
22. García Sanz R, González M, Vargas M, Chillón MC, Balanzategui A, Barbón M, Flores MT, San Miguel JF. Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas. Leukemia 1997; 11: 1915-1920.
23. Fizzolti M, Cimino G, Pisegna S, Alimena G, Quartarone C, Mandelli F, Pelica PG, Lo Coco F. Detection of homozygous deletions of the cyclin dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 1995; 85: 2685-2690.
24. Nakao M, Yokota S, Kaneko H, Seriu T, Koizumi S, Takaue Y, Fujimoto T, Misawa S. Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T lineage. Leukemia 1996; 10: 249-254.
25. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger P, Baylin SB, Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/INK4a/MTS1 in human cancers. Nature Med 1995; 1: 686-695.
26. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JPJ, Davidson NE, Sidransky D, Baylin SB. Inactivation of the p16h/CDKN2/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525-4530.
27. INK4a gene in multiple myeloma. Br J Haematol 1998; 101: 558-564.
28. Urashima M, Teoh G, Ogata A, Chauhan D, Treon SP, Sugimoto Y, Kaihara Ch, Matasuzaki M, Hoshi Y, De Caprio JA, Anderson KC. Characterization of p16 INK4A expression in multiple myeloma and plasma cell leukemia. Clin Cancer Res 1997; 3: 2173-2179.
29. Martínez B, Fernandez-Piqueras J, García MJ, Arranz E, Gallego J, Rivas C, Robledo M, Benitez J. Hypermethylation of a 5′ CpG island of p16 is a frequent event in non-Hodgkin's lymphoma. Leukemia 1997; 11: 425-428.
30. Klangby U, Okan I, Magnusson KP, Wendland M, Lind P, Wiman KGi. p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood 1998; 91: 1680-1587.
31. INK4a gene inactivation by deletions, mulations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998; 91: 2977-2984.
32. Lo KW, Cheung ST, Leung SF. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 1996; 56: 2721-2727.
33. INK4i genis in multiple myeloma. Br J Haematol 1997; 96: 98-102.
34. Ng MHL, Chung YF, Lo KW, Wickham NKW, Lee JCK, Huand DP. Hypermethylation of p16 and p15 genes in multiple myeloma. Blood 1997; 89: 2500-2506.
35. Chronic Leukemia-Myeloma Task force. Proposed Guideline for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep 1973; 4: 141-158.
36. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer Res 1975; 36: 842-848.
37. Orfao A, García Sanz R, López Berges MC, Vidriales MB, González M, Caballero MD, San Miguel JF. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodure double staining technique. Cytometry 1994; 17: 332-336.
38. Ocqueteau M, Ortao A, Almeida J, Bladé J, González M. García Sanz R, López-Berges MC, Moro MJ, Hernández J, Escribano L, Caballero MD, Rozman M, San Miguel JF. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998; 152: 1655-1665.
39. García Sanz R, Vargas M, González M, Chillón MC, Balanzategui A, Flores MT, Hernández J, Caballero MD, San Miguel JF. Detection of single and associated lessions of the bcl-1, bcl-2, bcl-6, c-myc, MLL, p53 and p16 genes in B-Cell non-Hodgkin's lymphoma. Value of molecular analysis for a better assignment of the histologic subtype. Haematologica 1998; 83: 209-216.
40. Ritter M, de Kant E, Huhn D, Neubauer A. Detection of DNA methylation in the calcitonin gene in human leukemias using differential polymerase chain reaction. Leukemia 1995; 9: 915-921.
41. Kosmo MA, Gale RP. Plasma cell leukemia. Semin Hematol 1987; 24: 202-208.
42. García Sanz R, Orfao A, González M, Tabernero MD, Bladé J, Moro MJ, Fernández-Calvo JM, Sanz MA, Pérez Simón JA, Rasillo A, San Miguel JF. Primary plasma cell leukemia: clinical, immunophenotypical, DNA ploidy and cytogenetic characteristics. Blood 1999; 93: 1032-1037.
43. González-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995; 55: 4531-4535.
44. Signal R, Ginder GD. DNA methylation. Blood 1999; 93: 4059-4070.
45. Jones PA. DNA methylation errors and cancer. Cancer Res 1996; 56: 2463-2467.